UBS Group
BBIO icon

UBS Group’s BridgeBio Pharma BBIO Stock Holding History

UBS Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
+28,700
New +$2.01M ﹤0.01% 5061
2022
Q1 		– Sell
-4,200
Closed -$70K – 10244
2021
Q4 		$70K Buy
+4,200
New +$178K ﹤0.01% 6619

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

UBS Group's BBIO Position: Q2 2026 in Review

UBS Group reduced its BridgeBio Pharma (BBIO) stake by 13% in Q2 2026, selling an estimated $18.9M and leaving 1,757,152 shares worth $131M. The position accounts for 0.02% of the portfolio, ranked #940.

UBS Group first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $151M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • UBS Group held 1,757,152 shares of BridgeBio Pharma worth $131M as of Q2 2026.
  • UBS Group sold 269,669 BridgeBio Pharma shares in Q2 2026, an estimated $18.9M.
  • BridgeBio Pharma made up 0.02% of UBS Group's portfolio in Q2 2026, its #940 holding.
  • UBS Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • UBS Group's BridgeBio Pharma position peaked at $151M in Q1 2026.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.